Biogen (BIIB) Wells Fargo 21st Annual Healthcare Conference summary

Strategic focus and portfolio diversification

• Emphasis on diversifying the pipeline beyond neurology, expanding into immunology and nephrology, and executing transactions like HI-Bio and Apellis to support this shift.

• Ten phase III programs are now underway, with pivotal readouts expected in the fourth quarter, marking a critical growth point.

• Capital allocation is disciplined, prioritizing assets with the highest conviction and optimizing R&D investments.

• The Fit for Growth initiative redeployed investments from legacy MS products to new launches, supporting long-term growth.

• Expansion into nephrology leverages validated endpoints and commercial synergies, with felzartamab positioned as a foundational asset.

Financial management and operational efficiency

• Ongoing focus on managing OpEx while investing in launches and pipeline development to drive both top and bottom-line growth.

• Apellis acquisition expected to deliver $250 million in annualized savings by end of 2027, mainly from R&D and G&A optimization.

• Growth portfolio now offsets legacy MS erosion, with high-margin products in rare and unmet need areas supporting profitability.

• Commitment to paying down Apellis-related debt by 2027, maintaining sufficient capital for early-stage investments.

Product pipeline and commercial strategy

• Felzartamab targets AMR as a primary opportunity, with expansion into additional nephrology indications and potential in autoantibody-driven diseases.

• Apellis deal brings SYFOVRE and C3G assets, with focus on patient acquisition, persistency, and commercial campaigns to drive growth.

• TYSABRI demonstrates resilience against biosimilar competition due to strong patient and physician relationships and unique assay support.

• SMA franchise stabilized with high-dose SPINRAZA adoption and development of a port device to ease administration, supporting future growth.

• Continued investment in lupus and rare disease assets, with upcoming readouts in SLE and CLE, and collaborations to build expertise.